Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • pharma-news
    • Sanofi delays Slump...

    Sanofi delays Slump Sale and transfer of Ankleshwar plant

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2020-03-30T15:30:29+05:30  |  Updated On 30 March 2020 3:30 PM IST
    Sanofi delays Slump Sale and transfer of Ankleshwar plant

    Gujrat: Sanofi has announced the change in date for the closing of a transaction relating to Slump Sale and transfer of its manufacturing facility of the Company at Ankleshwar, Gujarat.

    "This has reference to our letter dated 11th September 2019 wherein we intimated you that the Board of Directors of Sanofi India Limited at its meeting held on 10th September 2019, approved a transaction for the slump sale and transfer of the manufacturing facility at Ankleshwar, Gujarat to Zentiva Private Limited", Sanofi stated in a filing

    "The closing of this transaction was subject to the approval of the shareholders by way of postal ballot and certain regulatory approvals as described in the Business Transfer Agreement. It was anticipated that the closing of this transaction will be achieved on or before 31st March 2020 and accordingly expected closing dates were announced in disclosures to stock exchanges and postal ballot notice to the shareholders", It further stated

    "The shareholders of the Company approved this transaction by way of postal ballot on 30th October 2019", the company added

    "We would like to intimate you that due to a delay in receiving regulatory approvals, the closing of this transaction is not likely to be achieved by 31st March 2020. It is now expected that the closing of this transaction will be achieved during the quarter ending 30th June 2020", Sanofi said

    Read also: Regeneron, Sanofi begin testing use of Arthritis Drug Kevzara to treat COVID-19


    sanofislump-saleAnkleshwar

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok